Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM229PE | TNBC | - | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 11058.144 | 0.9658 | 0.9674 | 2.1171 | |
| SUM229PE | TNBC | - | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 11058.144 | 0.8752 | 0.8780 | 2.1171 | |
| SUM229PE | TNBC | - | Temsirolimus | MTOR | MTOR | 0.213 | uM | 11058.144 | 0.8776 | 0.8804 | 2.1171 | |
| SUM229PE | TNBC | - | Temsirolimus | MTOR | MTOR | 1.07 | uM | 11058.144 | 0.8084 | 0.8088 | 2.1171 | |
| SUM229PE | TNBC | - | Temsirolimus | MTOR | MTOR | 5.33 | uM | 11058.144 | 0.7964 | 0.7961 | 2.1171 | |
| SUM229PE | TNBC | - | Temsirolimus | MTOR | MTOR | 26.7 | uM | 11058.144 | 0.4741 | 0.4058 | 2.1171 | |
| SUM229PE | TNBC | - | Temsirolimus | MTOR | MTOR | 133 | uM | 11058.144 | 0.0079 | -0.7969 | 2.1171 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 10695.144 | 0.6638 | 0.4345 | 1.2333 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 10695.144 | 0.5100 | 0.1585 | 1.2333 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 10695.144 | 0.4509 | 0.0485 | 1.2333 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 10695.144 | 0.4805 | 0.1039 | 1.2333 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.213 | uM | 10695.144 | 0.4692 | 0.0827 | 1.2333 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 1.07 | uM | 10695.144 | 0.4385 | 0.0251 | 1.2333 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 5.33 | uM | 10695.144 | 0.4177 | -0.0146 | 1.2333 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 26.7 | uM | 10695.144 | 0.2515 | -0.3470 | 1.2333 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 133 | uM | 10695.144 | 0.0051 | -0.9723 | 1.2333 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 11852.144 | 0.9589 | 0.9359 | 1.2876 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 11852.144 | 0.7248 | 0.5576 | 1.2876 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 11852.144 | 0.5582 | 0.2717 | 1.2876 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 11852.144 | 0.4691 | 0.1110 | 1.2876 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.213 | uM | 11852.144 | 0.5016 | 0.1703 | 1.2876 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 1.07 | uM | 11852.144 | 0.4815 | 0.1337 | 1.2876 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 5.33 | uM | 11852.144 | 0.5054 | 0.1773 | 1.2876 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 26.7 | uM | 11852.144 | 0.2429 | -0.3336 | 1.2876 | |
| SUM52PE | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 133 | uM | 11852.144 | 0.2475 | -0.3240 | 1.2876 |